Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2M | P61081 | 5/20 | 0.46 |
| ▸ | DCUN1D1 | Q96GG9 | 5/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13930717 | 0.95 | UBE2M (0.45) | UBE2MDCUN1D1EPHX2KMT2ASMN1; SMN2 | |
| SCHEMBL13930707 | 0.92 | UBE2M (0.44) | UBE2MDCUN1D1EPHX2KMT2ASMN1; SMN2 | |
| SCHEMBL13930712 | 0.92 | SMN1; SMN2 (0.49) | UBE2MDCUN1D1EPHX2KMT2ASMN1; SMN2 | |
| SCHEMBL13930692 | 0.91 | UBE2M (0.49) | UBE2MDCUN1D1EPHX2KMT2ASMN1; SMN2 | |
| SCHEMBL13930716 | 0.88 | UBE2M (0.46) | UBE2MDCUN1D1EPHX2KMT2ASMN1; SMN2 | |
| SCHEMBL13931081 | 0.87 | OPRM1 (0.44) | EPHX2KMT2ASMN1; SMN2MEN1MAPT | |
| SCHEMBL13930730 | 0.86 | UBE2M (0.51) | UBE2MDCUN1D1OPRM1 | |
| SCHEMBL13930704 | 0.85 | TPSAB1 (0.46) | UBE2MDCUN1D1EPHX2KMT2ASMN1; SMN2 | |
| SCHEMBL13952184 | 0.84 | OPRM1 (0.45) | UBE2MDCUN1D1EPHX2MAPTOPRM1 | |
| SCHEMBL13930670 | 0.82 | OPRM1 (0.47) | OPRM1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048291-A1 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use | EUROSCREEN S.A. (BE) | 2009-02-19 | — | — | US | disclosed |
| US-20090048291-A1 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use | EUROSCREEN S.A. (BE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048291-A1 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use | ALDH1A1, ABAT, ALDH18A1 | UBE2M 3695/4885DCUN1D1 3824/4885EPHX2 2311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.